-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
JZiNMQA/wEtvcHF9VUpAMRQXc8IqVgzispKiqMcQQSSTPAZrwRHHGDA2XScgO7X6
a4NnwYapSdAlsf0FYYJ+sQ==
UNITED STATES FORM 8-K CURRENT REPORT the Securities Exchange Act of 1934 Date of report (Date of earliest event reported)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
INSPIRE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31135 04-3209022
4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703-8466
Registrant's telephone number, including area code
(919) 941-9777_____________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
On August 11, 2009, the Compensation Committee of the Board of Directors of Inspire Pharmaceuticals, Inc. awarded a one-time, special cash bonus of $25,000 to each of Thomas R. Staab, II, Inspire's Chief Financial Officer and Treasurer, and Joseph M. Spagnardi, Inspire's Senior Vice President, General Counsel and Secretary, in recognition of their efforts in connection with Inspire's recent public offering of 25,555,555 shares of common stock.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Inspire Pharmaceuticals, Inc.
By: /s/ Christy L. Shaffer
Christy L. Shaffer, Ph.D.
President and Chief Executive Officer
Dated: August 13, 2009
-----END PRIVACY-ENHANCED MESSAGE-----